CHRISTINE CORALLINO: Open Payments
NPI 1366961310 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,836 in 86 payments from 21 companies in 2025. Trend: 2023 $1,174 · 2024 $697 · 2025 $1,836
Food & beverage: $1,836
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $254 |
| ABBVIE INC. | 15 | $217 |
| Janssen Biotech, Inc. | 11 | $204 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $151 |
| QOL Medical, LLC | 4 | $132 |
| Madrigal Pharmaceuticals | 3 | $122 |
| Gilead Sciences, Inc. | 4 | $107 |
| GENZYME CORPORATION | 3 | $87 |
| Phathom Pharmaceuticals, Inc. | 5 | $84 |
| Novo Nordisk Inc | 4 | $77 |
Products named: ENTYVIO, TREMFYA, XIFAXAN, Sucraid, REZDIFFRA, DUPIXENT, RINVOQ, VOQUEZNA.
Industry payments across MA — which companies pay providers there.
